Abstract
Introduction
Chronic heart failure (CHF) is associated with neurohormonal activation, increased oxidative stress (OS), chronic inflammation and other mechanisms that contribute to continuous cardiac remodeling and heart failure progression. Despite impressive advances in the knowledge of heart failure mechanisms and the improvement of treatment, patients with CHF have a dismal prognosis.
Increased serum uric acid (sUA) is strongly related to a poor prognosis in moderate -severe CHF (1, 2) . The risk of mortality markedly increases at sUA levels higher than 7 mg/dl (3, 4, 5, 6) . Hyperuricemia might be the consequence of increased xanthine-oxidase activity, which generates superoxide free radicals proportionally to uric acid synthesis (7, 8, 9) . Thus, elevated sUA levels could be a marker of impaired oxidative metabolism linked to the chronic inflammatory response in CHF (10, 11, 12) .
The aim of the study was to assess the relationship between sUA, OS and inflammation markers and the severity of left ventricular (LV) dysfunction in patients with moderate-severe, stable CHF and reduced systolic function, under optimal medical treatment according to current guidelines (13) .
Study group and methods

Study population
Fifty-seven patients, 43 men and 14 women, with a mean age of 60 ± 12 years, with CHF NYHA class III and ejection fraction (EF) < 40% were included in the study. Patients with decompensated heart failure, evolving ischemia, significant valvular disease, and severe pulmonary or liver disease were not included in the study. Patients were clinically stable during the past four weeks before inclusion, without renal dysfunction, and under optimal medical therapy (betablockers, angiotensin converting enzyme inhibitors, furosemide, spironolactone and digoxin). None of the patients were taking urate lowering medication. The patients were informed about the methodology and purpose of the current research study and subsequently signed a written informed consent. The present study was approved by the local Ethics Committee.
Methods
Echocardiography and laboratory tests were performed in all patients, after a comprehensive clinical examination. 
Echocardiographic Data
The echocardiographic examination was performed using an Aloka 4000 ultrasound machine with a 2.5 MHz probe. Echocardiography studies were performed according to standard recommendations of the European Association of Cardiovascular Imaging. The LV end-diastolic (LVEDV), LV end-systolic volumes (LVESV) and EF were assessed using the Simpson method. The mitral peak velocity of early filling (E), the deceleration time of early filling velocity (DTE) and the peak velocity of late filling (A) were evaluated. The septal and lateral annular velocities (e') were measured using tissue Doppler echocardiography. One third of the patients had atrial fibrillation and the E/A ratio was not available. Therefore, the LV diastolic function and LV filling pressures were estimated using the E/e'ratio, i.e. the ratio between early filling velocity (E) and the averaged annular velocities (e'). A value of E/e' ratio ≥ 13 was considered a marker of elevated LV filling pressures.
Laboratory evaluation sUA levels were assessed using enzymatic-colorimetric methods using Roche Diagnostics (normal range: ≤ 7.2 mg/dL).
The N-terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP) was measured using Roche Cardiac Reader kit (normal range: <125 pg/mL).
Malondialdehyde (MDA) levels and myeloperoxidase (MPO) activity, as serum markers of OS, and paraoxonase-1 (PON-1) activity, as a marker of serum antioxidant activity, were assessed.
MDA was measured by ELISA OxiSelect TM MDA Adduct kit from CELL BIOLABS, INC. The MDA concentration was expressed in nmol/ mL (normal range: 0.27-1.02 nmol/mL). Myeloperoxidase (MPO) activity was determined spectrophotometrically at a wavelength of 405 nm, using o-Dianisidin as substrate, the enzymatic activity being expressed in IU/L (normal range 225-271 IU/L) (14) .
Paraoxonase-1 (PON-1) arylesterase activity was determined at a wavelength of 270 nm, the enzymatic activity being expressed in IU/L using phenyl acetate as substrate; one unit of paraoxonase activity was defined as a µM phenyl acetate hydrolyzed /min/ mL serum (normal range: 76.1 to 100.2 U/mL) (15) .
High sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL6) levels were assessed as markers of systemic inflammation.
hsCRP levels were measured with the high sensitive CRP ELISA IL International GMBH kit. The method used the ELISA immunoenzymatic technique (normal range: 1-3 mg/L).
IL-6 levels were assessed using the R&D Systems human IL-6 ELISA immunoassay kit, the results being expressed in pg/mL (normal range: 2.0 -10.9 pg/mL).
Serum creatinine levels were measured using Jaffe's method (normal range: 0.5-1.2 mgl/ dL) and the glomerular filtration rate was estimated by the Modification of Diet in Renal Disease (MDRD) equation.
Data analysis
Results are presented as mean ± standard deviation (SD) or median (min, max) for continuous numerical variables and percentages for categorical variables. The χ2 test, Fisher test were used to compare categorical variables, while Student t test was the test of choice for numerical variables. The Mann-Whitney with a 2-tailed hypothesis was used for variables with an independent (non-gaussian) distribution. Significant correlations between continuous variables were evaluated using Pearson's method. A p value less than 0.05 was considered statistically significant. Statistical analysis was performed using SPSS statistics, version 21.0.
Results
Among the fifty-seven patients diagnosed with NYHA III stable CHF with reduced EF (<40%), 43 patients (75%) had ischemic cardiomyopathy (Table I) . 18 (32%) CHF patients had permanent atrial fibrillation. The mean level of creatinine was 1.07 ± 0.19 mg/dL and the estimated glomerular filtration rate (eGFR) was 75.7 ± 16.05 mL/min/1.73m
2 . All patients were treated with betablockers and angiotensin converting enzyme inhibitors, 48 patients (84%) with loop diuretics (furosemide), 27 patients (47 %) with spironolactone and 20 patients (35 %) with digoxin.
The mean LVEF measured by echocardiography was 33.2 ± 6.1 % and the mean E/e' ratio was 11.5 ± 6.7 (Table I) . Based on the E/e' values, 38 patients (66 %) were classified as having high LV filling pressures (E/e ' ≥ 13) and 19 patients (34%) had normal LV filling pressures (E/e ' < 13).
The mean level of sUA was 7.9 ± 2.2 mg/dL, 61% of the patients having hyperuricemia. sUA was positively correlated to NT-proBNP levels (r = 0.44, p<0.001 ), and inversely correlated with LVEF (r = -0.24, p=0.048) (Figure 1) . Table II emphasizes the LVEF, NT-proBNP and sUA mean values in the study population and in relation to LV filling pressures. NT-proB-NP was 1625 ± 1268 pg/dL, significantly higher in patients with E/e'>13 (2531 ± 709 pg/mL vs 643.8 ± 430 pg/mL, p<0.003). EF was significantly lower in patients with E/e' > 13 (29.8 ± 3.9 % vs 34.6 ± 4.4 %, p<0.001). The mean sUA level was higher in patients with E/e' > 13 (8.6 ± 2.2 mg/dL vs 7.3 ± 1.4 mg/dL, p=0.08).
The values of OS markers, MDA, MPO and PON-1, and inflammatory markers, hsCRP and IL-6, in the study group and according to LV filling pressures are shown in Table II . MDA was significantly higher in patients with E/e' ≥ 13 (1.3 ± 0.2 vs 0.9 ± 0.2 nmoL/ml; p=0.04).
MPO activity was increased (310 ± 11 IU/L) not related with the E/e ' ratio (312 ± 10 U/L vs 307 ± 11 IU/L, p=0.34). There was no statistically significant difference between PON-1 activity (41.9 ± 15 U/mL) and E/e' (38.2 ± 10 U vs 37.5 (Figure 2 ). The median value of hsCRP was 6.1 (1.9, 23.8) mg/L, while the median value of IL-6 was 12 (0.7, 122.6) pg/mL. There was a significant correlation between sUA and IL-6 (r=0.56, p<0.001) (Figure 2 ).
Discussion
Many epidemiological studies found a relationship between sUA levels and cardiovascular diseases, such as arterial hypertension or coronary heart disease (16, 17, 18) . In patients with CHF the prevalence of hyperuricemia varies between 37% and 54% in patients with CHF, being higher, up to 70 % in patients hospitalized for worsening CHF with reduced EF (12, 19, 20, 21) . In our study, 61% patients with NYHA class III CHF and reduced EF had hyperuricemia. sUA was higher in patients with increased LV filling pressures (8.6 ± 2.2 mg/dL in patients with E/e'ratio ≥ 13 vs 7.3 ± 1.4 mg/dL, p=0.08). The relationship between sUA and the hemodynamic compromise in CHF was demonstrated invasively and non-invasively by the measurement of E/A ratio of the mitral inflow at echocardiography (2, 6, 22, 23, 24) . sUA correlated with severe diastolic dysfunction defined echocardiographically by restrictive mitral filling pattern (25) .
sUA level was associated with lower EF, both in stable and worsening heart failure (6,26). The significant relationship in between sUA and LVEF found in the present study (r = -0.24, p=0.048) has also been demonstrated in several CHF studies (24, 27, 28) . sUA level was related to NT-proBNP levels (24, 26) . Our data was similar to OPT-CHF trial results (29) .
The significant relationship between sUA and the severity of LV systolic and diastolic dysfunction in moderate-severe CHF qualifies sUA as a marker of CHF severity. In a validation study, sUA was the most powerful predictor of survival for patients with severe CHF, functional class III or IV, with a 7.4 relative risk of death in patients with sUA levels higher than 9.5 mg/ dl (1) . Hyperuricemia in CHF is attributed to multiple factors. Renal failure or long-term diuretic therapy reduce uric acid excretion. However, diuretic-induced hyperuricemia is more common with thiazides and uric acid retention under diuretic treatment is dose-dependent.
In CHF with normal kidney function, hyperuricemia is a consequence of increased production rather than reduced renal clearance (6, 26) . sUA is a marker of xanthine-oxidase up-regulation, triggered by local tissue ischemia or hypoxia, and generating free radicals proportionally to uric acid synthesis (12) . Large cohort studies demonstrated that hyperuricemia is a prognostic marker for poor outcomes for all cause mortality and CHF hospitalizations only in CHF patients without chronic kidney disease (6, 21) . In a recent meta-analysis of thirty-three studies assessing the relation between sUA and heart failure, the incremental elevation in sUA, by 1 mg/dL, increased risk of all cause mortality by 4% in patients with existing CHF and the odds of incident HF by 19% in the general population (26, 30) .
There is an imbalance of the oxidative metabolism in CHF. In our study MDA, a marker of lipid peroxidation, was higher in CHF patients with lower EF and increased LV filling pressures. Increased MDA levels were related CHF functional severity, the highest values being reported in patients with functional NYHA class III and IV (31, 32) . MPO activity was also increased, recent data suggesting a correlation between high MPO activity and CHF functional severity (33) . PON-1, a HDL-associated glycoprotein with antioxidant function, was reduced in CHF patients. Lower levels of PON-1 activity were also found in patients with idiopathic dilated cardiomyopathy and CHF (24) . The diminished PON-1 activity in CHF with low EF was a marker of worse prognosis, predicting a higher risk of incident long-term adverse events (34) .
The relationship between sUA, increased OS and reduced serum antioxidant capacity suggests that sUA is a marker of xanthine-oxidase up-regulation in CHF.
The markers of chronic inflammatory response were increased in CHF patients and IL-6 correlated with sUA levels(r=0.56, p<0.001).
The correlation between sUA and inflammatory cytokines (IL-6, TNF alpha), adhesion molecules and their soluble receptors was demonstrated in another study (4) . sUA emerged as the strongest predictor for inflammatory response, independent of diuretic dose and serum creatinine (4) . Uric acid levels parallels the chronic inflammatory response which occurs with increasing CHF severity (11) .
The correlations between sUA and OS and inflammation markers suggest that increased OS induces activation of leukocytes and endothelial cells, while promoting endothelial dysfunction. Activation of pro-inflammatory cytokines also contributes to increased sUA production (35) .
Study limitations
The limitations of this study are its small sample size, and a lack of a control group. However, these are only preliminary results, and the study will be extended to a larger number of CHF patients.
Conclusions
sUA is a metabolic biomarker of heart failure severity. Hyperuricemia in CHF without impairment of renal function may reflect an imbalance in oxidative stress, with increased xanthine-oxidase activity linked with chronic inflammatory response. Lowering sUA with xanthine-oxidase inhibitors may be a therapeutic option for heart failure treatment.
